with different epitopes on the 2-GPI molecule and the increased affinity of the divalent antigen-antibody complexes for phospholipid surfaces explains why some anticardiolipin antibodies have anticoagulant activity and some do not (Arnout J 2003) . This anticoagulant activity correlates best with the incidence of thrombosis , and a subset of lupus anticoagulants caused by anti-2-GPI antibodies with specificity for an epitope on domain I. In some patients the anticardiolipin antibody will react with immobilized cardiolipin in vitro but not prolong phospholipid-dependent coagulation tests. Similarly, some of the antiprothrombin antibodies can prolong coagulation tests and some will not. As with most autoimmune conditions, the etiology of APLS is not understood. It has been demonstrated that normal healthy individuals without APS have memory B cells that produce aPL antibodies; in a study of patients with infectious mononucleosis, 10 to 60 percent of immunoglobulin M aCL-producing cells expressed CD 27, the marker of memory B cells (Lieby P 2003) . Although antibodies against anionic phospholipid moieties arise during the course of infections such as syphilis and lyme disease, those are distinct from antibodies generated by patients with the syndrome because they generally recognize phospholipid epitopes directly and are not associated with the clinical manifestations of the syndrome. Reports of familial clustering of raised aPL antibody levels indicate that genetic susceptibility can play a role in their development (Donald I. Feinstein 2007) . In one study of 84 APLS patients, more than 35% had at least one relative, and more than 20% had two or more relatives, with evidence of at least one clinical feature of APS, such as thrombosis or recurrent fetal loss (Weber M 2000) . Many different mechanisms have been described for thrombosis during APLS, mainly after in-vitro experiments: (1) activation of endothelial cells by complexes of 2 GPI and anti-2 GPI, these complexes could bind to annexin 2 or even Toll-like receptors on the surface of endothelial cells (Zhang J 2005 , Fischetti F 2005 ; (2) platelet activation after direct binding of the 2 GPI, which targets the autoantibodies on the surface of these cells, the 2 GPI is selectively bound by the activator receptor apo ER 2 (Lutters BC 2003) ; (3) functional dysregulation of hemostasis by the presence of autoantibodies against natural anticoagulant proteins like annexin 5 and activated protein C; (4) abnormal fibrinolysis directly linked to the presence of APL (Cesarman-Maus G 2006) . APL can stimulate platelet aggregation (Lin YL 1992) , an effect that might be promoted via signalling through apolipoprotein E receptor 2(apoER2) receptors; the beta2GPI binding site for apo ER2 on platelets was localized to its domain V. Beta2GPI also has a dampening effect on platelet adhesion by interfering with the platelet-von Willebrand factor interaction, and consequently aPL antibodies, by interfering with this dampening, can increase platelet adhesion in flow systems (Hullstein JJ 2007) . Normal endothelial function includes control over thrombosis and thrombolysis, platelets and leukocyte interaction with the vessel wall, and regulation of vascular tone and smooth muscle proliferation. Several in vitro studies and studies on animal models have shown that incubation of endothelial cells with aPL from APLS patients generates different effects on endothelial function via 2 GPI. As a whole this might cooperate in sustaining endothelial perturbation that has been suggested to have a pivotal pathogenetic role in APS associated thrombosis (Stalc M 2006) . Because high-level aPLs may persist for years in asymptomatic persons, it is likely that vascular injury, endothelial cell activation, or both immediately precede the occurrence of thrombosis in those bearing the antibody (second-hit hypothesis). Of note, at least 50% of APLS patients with vascular factors possess other acquired thrombosis risk factors at the time of their events (Kaul M 2006 , Erkan D 2002 . Both persons congenitally lacking ß2GPI39 and ß2GPI knockout mice appear normal (Sheng Y 2001) . ß2GPI polymorphisms influence the generation of aPLs in individuals, but they have only a weak relationship to the occurrence of APLS. A cluster of 50 upregulated genes may have an effect on the occurrence of thrombosis in aPL-positive individuals(Potti A 2006).
Diagnostic criteria of the antiphospholipid syndrome
The international preliminary classification criteria for APLS was published in 1999 after a workshop in Sapporo, Japan (Wilson WA 1999) w e e k o f g e s t a t i o n , w i t h m a t e r n a l a n atomic or hormonal abnormalities and paternal and maternal chromosomal causes excluded. The first clinical aspect of the APLS is thrombosis, which can affect arterial or venous vessels, as well as small vessels, and must be confirmed by means of imaging studies and/or histopathology. Arterial thrombosis mainly occurs in the central nervous system. But all arteries can be effected and myocardial infarction, peripheral gangrene, aseptic osteonecrosis and adrenal insufficency can develop with respect to effected arterial site. The venous thrombosis commonly localizes to the deep veins of the limbs and can be complicated by pulmonary embolism. As in arterial thrombosis, any segment of the venous vasculature can be effected, which will induce different manifestations. A definitive diagnosis of APLS is based on fulfilling at least one of the Updated Sapporo Clinical criteria(vascular thrombotic event or pregnancy morbidity) and at least one of the laboratory criteria (Table 1 ). In general, medium titer aCL is considered 40 U or more and high titer, more than 80 U; titers between 20 and 40 U should be evaluated cautiously. Transient APL positivity is common during infections; thus documentation of the persistence(at least 12 weeks apart) of autoimmune APL is crucial for both diagnostic and therapeutic purposes. The choice of initial APL tests remains a subject of debate. In general, the LA test is more specific for APL-related clinical events. The specificity of aCL for APL-related clinical events increases with higher titers. The IgG isotype is more strongly associated with APL-related clinical events than the IgM isotype. In a patient with suspected APS, testing for LA and IgG/IgM aCL should be ordered initially. If these tests are negative or low-titer and there is still a high level of suspicion for APS, then testing for anti 2 GPI antibodies and IgA aCL/anti 2 GPI can be pursued (George D 2009) . Antiphospholipid antibody tests developed based on other phospholipids such as phosphatidylserine, phosphatidylinositol, or phosphatidylethanolamine or phospholipid-binding plasma proteins(such as prothrombin)
Laboratory criteria
are not yet well standardized and accepted.
Clinical features
Although any vasculature can be affected by thrombosis, stroke and transient ischemic attack are the most common presentations of arterial thrombosis, whereas deep vein thrombosis with or without pulmonary embolism is the most common presentation of venous thrombosis in APLS (George D 2009) . Antiphospholipid antibodies can cause both arterial and venous thrombosis in the same patient. Reccurent thromboses tend to occur in the same vascular distribution(venous followed by venous and arterial followed by arterial). in some studies the incidence of venous thrombosis (70%) is greater than the incidence of arterial thrombosis. (Galli M 1997 , Triplett DA 1995 . Superficial thrombophlebitis, superior vena cava syndrome, renal vein thrombosis, Budd Chiari syndrome, central retinal vein occlusion, pulmonary hypertension due to recurrent pulmonary embolism, and diffuse pulmonary hemorrhage due to microthrombosis are some of the thrombotic manifestations of APLS. Of unselected patients with antiphospholipid antibody, 1% to 2.5% per year will develop thromboembolism , Finazzi G 1996 ,and 10% to 25% of patients with deep venous thrombosis will be found to have antiphospholipid antibodies (Ginsburg KS 1992) .However, in a prospective population based study of 66140 individuals in Norway (Naess IA 2005) , elevated anticardiolipin antibody levels were not a risk factor for predicting an initial venous thrombosis. Thrombosis is more frequent as the level of anticardiolipin antibody increases, and medium and high titers (>40 GPL and/or MPL units) are more frequently associated with thrombotic events. Although some investigators believe that elevated levels of IgG or IgA isotypes are more common than IgM in patients with thrombotic complications, this has not been clearly established. The lupus anticoagulant or increased levels of anticardiolipin antibody must be persistently present on more than one occasion at least 12 weeks apart because the incidence of thrombotic complications is almost the same in patients with transiently positive tests as in patients with negative tests at two different time intervals. The persistent presence of elevated levels of anticardiolipin antibody has been shown to be associated with indices of in-vivo coagulation activation. In a study of patients with SLE (Ginsberg JS 1993) who were persistently anticardiolipin antibody-positive versus patients who were transiently positive or persistently negative, anticardiolipin antibody-positive patients had a higher mean level of F1+2 and fibrinopeptide A than patients who were transiently positive, persistently negative, or on warfarin therapy. The differences remained significant even if patients with prior thromboembolism were excluded from the analysis. These results suggest that the presence of persistently elevated levels of anticardiolipin antibody in SLE patients is associated with an ongoing prothrombotic state. Patients who are persistently positive for the lupus anticoagulant or who have persistently elevated levels of anticardiolipin antibody and suffer a thromboembolic event have a recurrence rate of approximately 50% within 2 years (Rosove MH 1992 . Recurrences tend to occur in most of the patients on the same side of the circulation as the initial event-venous recurrences after an initial venous event and arterial recurrences after an initial arterial event.
Treatment of venous thrombosis in APLS

General treatment
The standard of care for venous thromboembolism is continous infusion of intravenously delivered unfractionated heparin(UFH) and, more recently, subcutaneous low-molecular weight heparins(LMWH). DVT is associated with several possible complications, including recurrent nonfatal venous thromboembolism, postthrombotic chronic venous insufficiency, and nonfatal/fatal pulmonary embolism. The goals of therapy for DVT include the prevention of thrombus propagation, embolization, and early and late thrombus recurrence. Proper anticoagulation is the first critical step in the effective treatment of DVT.
Complications can develop soon after thrombus detection, presenting a narrow window of opportunity for a safe and effective intervention. The secondary stage of treatment involves the maintenance of adequate anticoagulation to prevent the development of recurrent thromboembolism. LMWH or fondaparinux is preferred for the initial anticoagulation of patients with deep vein thrombosis (Table 2) . LMWH and fondaparinux are as safe and as effective as continuous unfractionated heparin (UFH). Suitable patients can be safely treated with LMWH and fondaparinux in the outpatient setting. Heparin/fondaparinux should be continued for at least five days after the initiation of warfarin therapy and until International Normalized Ratio (INR) is > 2.0 for two consecutive days. Warfarin should be initiated 5 mg on day 1.
Treatment for venous thromboembolism with LMWH provides reliable anticoagulation levels when given subcutaneously on a weight-based dosing schedule. No laboratory monitoring of the intensity of anticoagulation is required for LMWH, except in special circumstances. Recent randomized controlled trials of the treatment of pulmonary embolism (PE) have shown LMWH to be as effective and safe as UFH. One randomized controlled trial of the treatment of venous thromboembolism (VTE) in 1,021 patients included 271 patients presenting with PE. In this study, there were no significant differences in outcomes following treatment with UFH versus LMWH. These studies used reviparin and tinzaparin. Two reviews agreed that LMWH may be efficacious in the treatment of PE, but cautioned that the LMWH products may not be equivalent to each other (Raskob 1999 ; Charland, 1998; Columbus Investigators, 1997; Simonneau, 1997 
Primary prophylaxis of thrombosis in patients with APL antibodies
The therapeutic approach in asymptomatic carriers of APL without prior thrombotic events is still controversial. Present evidence-based knowledge does not support the widespread use of aspirin in all these aPL-positive patients. Annual thrombosis risk in asymptomatic APL-positive patients range from 0% to 3.8% ( Finazzi G 1996 , Shah NM 1998 , being equivalent to that of major bleeding associated with the use of aspirin. The only randomized clinical trial (APLASA study) in which 98 asymptomatic persistently APL-positive individuals were randomized to recieve a daily dose of 81 mg of aspirin or placebo showed that these patients have a low overall annual incidence rate of acute thrombosis, and develop vascular events when additional risk factors are present (Erkan D 2007) . Therefore, according to the results of this trial, asymptomatic, persistently APLpositive individuals seem not to benefit from low-dose aspirin for primary thromboprophylaxis. However, a more realistic approach with a lower degree of evidence would be to stratify these individuals according to some clinical features such as the presence of traditional congenital or acquired procoagulant risk factors, the APL profile(persistently positive aCL and or anti-2 GPI antibodies at moderate/high titers), and the coexistence of an underlying autoimmune disease, to consider primary prophylactic therapy with low-dose 75-100 mg aspirin daily. It is known that SLE represents a prothrombotic condition and acts as strong thrombophilic risk factor, primarily related to the chronic systemic inflammation and renal involvement. Furthermore, one study has shown that prophylactic aspirin should be given to all patients with SLE to prevent both arterial and venous thrombotic manifestations, especially in patients with APL (Wahl DG 2000) . In the same study, the authors suggested that in selected patients with LA and a low bleeding risk, prophylactic oral anticoagulant therapy may provide higher utility. Therefore, there is currently consensus for primary thromboprophylaxis in these patients, mainly with low-dose aspirin. An alternative to aspirin in SLE patients may be hydroxychloroquine. There are many evidences for the protective role of this old drug against the development of both venous and arterial thrombosis (Ruiz-Irastorza G 2006 , Erkan D 2002 . All nonthrombotic APL-positive subjects should be encouraged to stop smoking. Cessation of oestrogen -containg oral contraceptive use and treatment of other vascular risk factors if present are additional recommended therapeutic measures. At least half of patients with APLS with vascular events also have another reversible risk factors which are not related to APLS at time of thrombosis (Erkan D 2002) . Therefore, identification and elimination of these risk factors and agressive prophylaxis during highrisk periods, are crucial for the primary thrombosis prevention in asymptomatic persistently APL-positive individuals. Serious perioperative complications including catastrophic antiphospholipid syndrome(CAPS) may occur despite prophylaxis in APL-positive individuals as they are at additional risk for thrombosis when undergoing surgical procedures. Therefore, perioperative strategies should be clearly identified before any surgical procedure, pharmacological, and physical antithrombosis interventions should be vigorously used; periods without anticoagulation should be kept to an absolute minimum (George D 2009 ).
Therapy for acute thrombosis and secondary propylaxis of thrombosis in patients with antiphospholipid syndrome
Therapy for thrombosis associated with the APLS should be guided by the knowledge that recurrence is common. In one study, patients who had discontinued oral anticoagulation had a 50% probability of recurrence in 2 years and a 78% recurrence in 8 years (Derksen RHWM 1993) . Similar results have been published by others with a recurrence rate of 10% to 30% per year , Rosove MH 1992 . Three prospective studies reported that there was an increased risk of recurrence that varied from 10% to 67% per year , Schulman S 1998 , Kearon C 1999 , Kearon C 2003 , Ortel TL 2005 . In most reports the incidence of recurrence is highest in the first 6 months after discontinuing anticoagulant therapy. Although it was initially thought that prevention of venous recurrence required high-intensity warfarin with a target INR of 3.5, evidence has been accumulating from recent studies that standard intensity warfarin (INR 2 to 3) can almost completely abrogate recurrence of venous thromboembolic disease (Crowther MA 2003 , Finazzi G 2005 . The pooled data from these two studies revealed no difference in recurrent thrombosis between moderate-intensity warfarin (INR 2 to 3) and high-intensity (INR 3 to 4), nor was there a greater bleeding risk. As the data from several studies have demonstrated that patients with antiphospholipid syndrome have a high risk for recurrent venous thromboembolic disease after anticoagulation is discontinued, many feel that anticoagulation should be continued indefinitely. The American College of Chest Physicians recommends treatment for 12 months and consideration of indefinite therapy after an initial event (Ortel TL 2005 , Buller HR 2004 . Because of the efficacy of warfarin therapy in preventing recurrences, the use of corticosteroids and other immunosuppressive agents to suppress antibody production in the absence of autoimmune disease is not recommended. Monitoring anticoagulant therapy may be difficult in patients with lupus anticoagulants and a prolonged PTT. It is mandatory when using unfractionated heparin to monitor therapy using a specific heparin assay, such as the one dependent on factor Xa inhibition (therapeutic range, 0.3 to 0.7). In most instances, it is preferable to use low-molecular-weight heparin in therapeutic doses, which usually eliminates the need for monitoring. When using warfarin, the optimal INR for patients with lupus anticoagulants is controversial, because patients with lupus anticoagulants may have a variably prolonged prothrombin time,and various thromboplastins have a different sensitivity in the presence of a lupus anticoagulant.Therefore, it is possible that in various studies of therapy in patients with lupus anticoagulants that the degree of anticoagulation is overestimated, and the target INR of 3.0 noted earlier might be an overestimate because of the presence of the lupus anticoagulant (Donald I. Feinstein 2007) . Rarely, patients may continue to have recurrent venous thromboembolic events despite INR values in the therapeutic range. Recurrent thrombotic events despite therapeutic anticoagulation require evaluation and modification of all non-APL thrombosis risk factors. Warfarin therapy is generally increased to highintensity(INR, 3.0-4.0). Other options include adding low-dose aspirin, hydroxychloroquine, and/or statins to warfarin or switching to low-molecular weight heparin. There are no randomized controlled studies investigating the effectiveness of any of these approaches. Based on many cohort studies ,subgroup analysis and two randomized controlled studies, a recent review (Ruiz-Irastorza G 2007) suggests that patients with definite APLS with a first venous thrombosis should be treated with prolonged oral anticoagulation at a target INR of 2.0-3.0 and those with an arterial event at an 3.0-4.0. So, the best secondary thromboprophylaxis in patients with definite APLS is long-term anticoagulation at a target INR of 2.0-3.0. Patients with recurrent venous thrombotic events despite optimal anticoagulation should be treated with warfarin at an INR of 3.0-4.0.
